Translational Notes: A conversation with Gregory Verdine

 

Table 1. Companies developing new classes of peptide-based therapeutics.

Company

Platform technology

Clinical stage programs

Aileron Therapeutics Inc.

Chemically cross-linked helices

 

Anchor Therapeutics Inc.

Lipopeptides for modulating G protein-coupled receptors

 

Angiochem Inc.

Blood brain barrier-penetrating peptides conjugated to drugs

Partner Geron Corp. (NASDAQ:GERN) to start Phase II trial of GRN1005 (ANG1005), an angiopep-2 vector conjugated to three paclitaxel molecules, in 2H11 to treat brain metastases

Bicycle Therapeutics Ltd.

Chemically constrained bicyclic peptides

 

Cosmix Verwaltungs GmbH

d-Peptides

 

Esperance Pharmaceuticals Inc.

Membrane-disrupting peptides conjugated to ligands

EP-100, a fusion protein consisting of a luteinizing hormone-releasing hormone (LHRH) ligand conjugated to a membrane-disrupting peptide, is in Phase I testing for various cancers

Mercator Therapeutics Inc.

Targeting peptides conjugated to drugs

 

Pepscan Therapeutics B.V.

Chemically constrained peptides

 

PeptiDream Inc.

Cyclic peptides incorporating non-natural amino acids

 

Polyphor Ltd.

Cyclic peptide-like molecules that mimic protein epitopes

POL7080, a modified peptide targeting the Pseudomonas LPS-assembly protein (OstA; LptD; lmp), is in Phase I trials for pseudomonas infections

Ra Pharmaceuticals Inc.

Undisclosed